Department of Anesthesiology and Perioperative Medicine, USA.
Curr Opin Anaesthesiol. 2010 Apr;23(2):263-8. doi: 10.1097/ACO.0b013e32833723fe.
To update readers on recent literature regarding treatment of coagulopathy for patients with life-threatening bleeding, highlighting emerging therapeutic options, controversial topics, and ongoing clinical trials.
Massive transfusion protocols featuring immediate availability of blood products and multidisciplinary communication reduce mortality and conserve resources. There is a growing consensus that immediate administration of plasma and platelet units in a 1: 1: 1 ratio with red cell units reduces early mortality. Lyophilized and recombinant blood product components may have advantages over traditional blood products in certain clinical circumstances.
Massive transfusion protocols standardize treatment of the coagulopathy of massive bleeding, leading to rapid restoration of hemostasis and decrease in early mortality.
更新读者对危及生命的出血患者凝血障碍治疗的最新文献，重点介绍新出现的治疗选择、有争议的话题和正在进行的临床试验。
大量输血方案强调血液制品的即时可用性和多学科沟通，可降低死亡率并节约资源。越来越多的共识认为，立即输注 1:1:1 比例的血浆和血小板与红细胞单位可降低早期死亡率。在某些临床情况下，冻干和重组血液制品成分可能比传统血液制品具有优势。
大量输血方案使大量出血的凝血障碍治疗标准化，导致止血迅速恢复，早期死亡率降低。
